(Q37454373)

20 August 2017

1 reference

title

Cardiovascular risk and management in chronic kidney disease (English)

1 reference

20 August 2017

1 reference

Marcello Tonelli

2

0 references

author name string

Diana Rucker

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Nature Reviews Nephrology

20 August 2017

published in

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

287-296

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2009.42

20 August 2017

exact match

0 references

cites work

Cystatin C as a risk factor for outcomes in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Guidelines for the management of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cardiovascular disease in transplant recipients: current and future treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Premature cardiovascular disease in chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cardiac disease in chronic uremia: can it explain the reverse epidemiology of hypertension and survival in dialysis patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Hyperlipidemia in patients with chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition Examination Survey (1991-1994)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Lipoprotein metabolism and lipid management in chronic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effect of pravastatin in people with diabetes and chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

A1C and survival in maintenance hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Is there a need to optimize glycemic control in hemodialyzed diabetic patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Survival advantages of obesity in dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Correction of anemia with epoetin alfa in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effect of early correction of anemia on the progression of CKD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Vascular calcification in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Serum phosphate levels and mortality risk among people with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Microalbuminuria. Implications for micro- and macrovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cardiovascular risk in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Inflammation in end-stage renal disease: sources, consequences, and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Thrombophilia and the risk for hemodialysis vascular access thrombosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Beyond blood pressure: new roles for angiotensin II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effect of chronic renal failure on nitric oxide metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Relevance of oxidative pathways in the pathophysiology of chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Homocysteine and coronary artery disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Relationship between homocysteine and mortality in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.42

The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing

31 March 2020

1 reference

12 December 2020

K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients

1 reference

12 December 2020

Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group

1 reference

12 December 2020

Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients.

1 reference

12 December 2020

Impact of hematocrit on morbidity and mortality

1 reference

12 December 2020

Clinical epidemiology of cardiovascular disease in chronic renal disease

1 reference

12 December 2020

Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2009.42

1 reference

Dimensions Publication ID

20 August 2017

1003780229

0 references

1 reference